Factors Associated with Acute Sialadenitis in Thyroid Cancer Patients Received High–Dose Radioactive Iodine
Abstract
This retrospective study aimed to explore the factors associated with acute sialadenitis in thyroid cancer patients who received high–dose radioactive iodine (RAI–131). The study population was the patients with differentiated thyroid carcinoma (DTC) treated with high–dose RAI–131 who admitted to radiotherapy at ward 5A, Srinagarind hospital during 1st January – 31st December, 2019. The 120 samples were recruited by systematic random sampling. The research instruments consisted of personal and health data record form and the record form for factors associated with acute sialadenitis in thyroid cancer patients treated with high–dose RAI–131. Data were analyzed using descriptive statistics and logistic regression.
The study findings showed that the samples consisted of 120 cases, aged 18–82 years, (mean = 53.8, S.D. = 14.72), most of them were female (81.7%). They had no underlying disease (65%), had total thyroidectomy (86.7%), cell pathology was papillary thyroid carcinoma (PTC) (80.8%). The RAI–131 administered dose was 150 millicuries (91.7%) and the average cumulative dose was 229.92 millicuries (S.D. = 13.17). Most of them had first RAI–131 receiving (65.2%). The prevalence of acute sialadenitis was 28.33%. The factors associated with acute sialadenitis in the thyroid cancer patients received high–dose RAI–131 were age (OR = 2.91, 95%CI =1.07– 8.73, p = 0.018), number of RAI–131 treatment (OR = 3.43, 95%CI = 1.14 – 12.40, p = 0.012) and the 30–150 millicuries cumulative dose of RAI–131 (OR = 3.98; 95%CI = 1.32 to 14.31, p = 0.004).
The results recommend that nurses who care thyroid cancer patients receiving high–dose RAI–131 should pay attention to the patients with first RAI–131 receiving, 30–150 millicuries cumulative dose of RAI–131 and aged less than 60 years to prevent acute sialadenitis.
Keywords: Acute sialadenitis, Thyroid cancer, High–dose radioactive iodine, RAI-131
